[EVENT] ISPOR 22nd Annual Meeting 2017

Please join the Ipsos Healthcare team who’ll be presenting data on key topics in NASH, Oncology, Diabetes and Obesity, as well as exhibiting at the 22^nd International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting.

Led by Ipsos’ Marco Dibonaventura, one of our studies in NASH conducted using data from the Ipsos Healthcare NASH Therapy Monitor - a retrospective medical chart review of patients with NAFLD in the US and EU5 – will provide key insights including:

• Patients with non-alcoholic fatty liver disease (NAFLD) in the United States are only examined for NASH in 50% of cases.
• Identification of the percentage of patients who had a complete NAFLD Activity Score (NAS)*.
• Determination of patient characteristics most strongly associated with a complete NAS measurement.
• Potential under diagnosis of NASH.
• Understanding the presence of NASH cannot be definitively determined without this NAS assessment.
• Improved early detection of NASH can dramatically affect patient outcomes and societal costs, particularly with new treatments becoming available in the future.

For a full list of Ipsos poster presentations at the conference, please click here.

For conference details, please visit the ISPOR website. Please visit us at BOOTH # 312.  We look forward to seeing you in Boston!

*The American Association for the Study of Liver Diseases recommends that a NAS score of 3 or above indicates the presence of NASH.